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Purpose: To study the disease course of RPE65-associated inherited retinal degener-
ations (IRDs) as a function of the genotype, define a critical age for blindness, and identify
potential modifiers.
Methods: Forty-five patients with IRD from 33 families with biallelic RPE65mutations, 28
stemming from a genetic isolate. We collected retrospective data from medical charts.
Coexisting variants in 108 IRD-associated genes were identified with Molecular Inversion
Probe analysis.
Results:Most patients were diagnosed within the first years of life. Daytime visual function
ranged from near-normal to blindness in the first four decades and met WHO criteria for
blindness for visual acuity and visual field in the fifth decade. p.(Thr368His) was the most
common variant (54%). Intrafamilial variability and interfamilial variability in disease severity
and progression were observed. Molecular Inversion Probe analysis confirmed all RPE65
variants and identified one additional variant in LRAT and one in EYS in two separate patients.
Conclusion: All patients with RPE65-associated IRDs developed symptoms within the first
year of life. Visual function in childhood and adolescence varied but deteriorated inevitably
toward blindness after age 40. In this study, genotype was not predictive of clinical course.
The variance in severity of disease could not be explained by double hits in other IRD genes.
RETINA 40:1812–1828, 2020
R PE65-associated inherited retinal degenerations(IRDs) are rare, and they account for 5% to
10% of all autosomal recessive childhood-onset IRDs.1
Historically, a distinction was made between patients
with Leber congenital amaurosis (LCA) and early-
onset severe retinal dystrophy (EOSRD) or severe early
childhood-onset retinal dystrophy (SECORD). LCA was
first described by Theodore Leber2 in 1869. The oblig-
atory symptoms were congenital amaurosis or highly
impaired vision, a large discrepancy between visual
function and fundus appearance, an autosomal recessive
inheritance pattern, and absent or markedly reduced elec-
trical retinal activity. In 1916, he described a similar
disorder with a later onset (6–7 years old) and a milder
course of the disease, that was later referred to as
EOSRD or SECORD.3 Nowadays, LCA, EOSRD, and
SECORD are considered as part of the same spectrum
because of clinical and molecular overlap and account
for 5% of all IRDs.4
The RPE65 (retinal pigment epithelium [RPE]-
specific protein 65 kDa) gene is exclusively expressed
in the RPE, where the protein acts as an isomerase and
transforms all-trans-retinyl esters into 11-cis retinol.5
11-cis retinol is subsequently converted into 11-cis
retinal, which regenerates the visual pigment, chromo-
phore, in photoreceptor cells after light exposure.
Without normal functioning RPE65 protein, 11-cis ret-
inal is depleted, and photoreceptor function becomes
jeopardized. Rod photoreceptors depend exclusively
on 11-cis retinal from the RPE; consequently, an
RPE65 protein deficiency leads to severe night blind-
ness from birth.5 Cone photoreceptors can access
11-cis retinal from an alternative visual pathway tak-
ing place in Müller cells.6 Hence, visual acuity in
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daylight remains relatively preserved during child-
hood. Superimposed on the biochemical dysfunction
of the visual cycle, there is a degenerative component,
which adds to the development of severe visual
impairment. The origin of this degeneration remains
unknown, despite increased understanding of the
visual cycle.
Multiple therapeutic approaches for RPE65-associ-
ated IRDs have been evaluated such as pharmacolog-
ical substitution therapy with oral 9-cis retinal,7 an
artificial chromophore, and gene augmentation ther-
apy8–11 to bypass the biochemical blockade caused
by RPE65 mutations. Although these therapies have
shown to partially reverse the dysfunctional compo-
nent,7–11 they have not succeeded to slow or arrest
the degenerative process in humans. The limitations
of these trials can be attributed to many reasons, but
the incorrect timing of administration within the clin-
ical course of the disease may be an important expla-
nation. Preferably, therapeutic interventions are
administered before a critical number of photorecep-
tors are lost because of degeneration12 and retinal re-
modeling.13 Although it is recognized that retinal
degeneration in RPE65 starts early in life,14,15 exact
figures from a large group of patients about the clinical
course and its determinants such as the RPE65 geno-
type and genetic modifiers are scarce,8,16–37 but are of
utmost importance as gene augmentation therapy has
been approved by the Food and Drug Administration
(FDA) in December 2017 and is becoming available
for the RPE65 population.
We studied data from two cohorts of patients with
RPE65 IRDs: an inbred cohort from a genetic isolate
and an outbred cohort with unrelated families from our
clinics. This unique combination offers the opportu-
nity to search for genotype–phenotype correlations
and to investigate whether subjects with identical
RPE65 variants experience a similar natural course of
the disease. We, therefore, performed a longitudinal
study in patients from this genetic isolate and unrelated
families and studied the natural course of the disease
as a function of the RPE65 genotype and assessed the
critical age for development of blindness.
In the genetic isolate, we have also come across
patients with IRDs caused by variants in other IRD-
associated genes such as LRAT, FAM161A, and
USH2A. Using recently developed Molecular Inver-
sion Probes (MIPs) technique, we also examined 108
other IRD genes to identify potential modifiers of
RPE65-mediated IRDs. Especially genes that are part
of the visual cycle (ABCA4, LRAT, RDH12, and
RLBP1) were of interest.
Methods
Subjects
In 1959, Schappert-Kimmijser et al described an
isolated population living in the northwest of the
Netherlands with a relatively high prevalence of LCA.
In 2003 Yzer et al38 discovered a founder mutation in
the RPE65 gene (p.Tyr368His) in 14 patients from this
genetic isolate. For this study, we gathered longitudi-
nal data from these original 14 patients (Table 1). We
included 14 more patients from the same genetic iso-
late and 16 patients with RPE65-associated IRDs from
our ophthalmogenetic outpatient clinics in Rotterdam.
Finally, we queried our partners of the RD5000 con-
sortium,39 resulting in a cohort of 45 patients from 33
families with RPE65-associated IRDs.
Medical records were reviewed to extract medical
history, family history, molecular diagnosis, and longi-
tudinal visual function testing. Fifteen patients were
invited for a complete ophthalmic examination with
visual function assessment and fundus imaging because
they had not been evaluated in the past 5 years.
Prospective clinical data from another 17 patients were
gathered during the period of this study (January 1st,
2014–April 30th, 2017) as part of routine follow-up.
Best-corrected visual acuity (BCVA) was measured in
preschool children with Lea symbols40 or E charts. In
literate patients, Early Treatment Diabetic Retinopathy
Study (ETDRS) or Snellen charts were used. All BCVA
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Table 1. Demographic and Genetic Characteristics of Patients Included in this Study
ID Gender
Age Last
Visit
Follow-up
(years)
DNA
Variation
Protein
Variation DNA Variation Protein Variation MIPs Variant
A1* M 20 17 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
B1* M 37 37 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
B2* M 38 7 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
C1* M 43 38 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
D1*,8 M 26 18 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
E1* M 34 29 c.715T.G p.(Tyr239Asp) c.715T.G p.(Tyr239Asp)
F1* M 18 18 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
G1 M 27 20 c.989 G.A p.(Cys330Thr) c.989 G.A p.(Cys330Thr)
H142 M 7 4 c.138delG p.(Pro47Glnfs*47) c.138delG p.(Pro47Glnfs*47)
H242 F 8 6 c.138delG p.(Pro47Glnfs*47) c.138delG p.(Pro47Glnfs*47)
I1 F 24 9 c.715T.G p.(Tyr239Asp) c.715T.G p.(Tyr239Asp)
J1*,8 M 10 8 c.1102T.C p.(Tyr368His) c.11+5 G.A p.(?)
K1* F 7 3 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His) EYS:c.1673 G.A; p.(Trp558*)
K2* F 10 8 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His) EYS:c.1673 G.A; p.(Trp558*)
L1*,8 F 12 0 c.11+5 G.A p.(?) c.11+5 G.A p.(?)
M142 M 27 7 c.1102T.C p.(Tyr368His) c.208T.G p.(Phe70Val)
N1 F 41 0 c.271C.T p.(Arg91Trp) c.715T.G p.(Tyr239Asp)
O1* M 24 22 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
O2* F 33 27 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
O3*,25 M 34 31 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His) LRAT:c.12del; p.(Met5Cysfs*54)
P1 F 48 32 c.1102T.C p.(Tyr368His) c.361del p.(Serf121 fs)
Q1 M 29 9 c.859 G.T p.(Val287Phe) c.859 G.T p.(Val287Phe)
R1* M 15 13 c.1102T.C p.(Tyr368His) c.11+5 G.A p.(?)
S1*,8 M 20 18 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
T1* F 5 3 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
T2* F 0 NA c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
U1* F 29 24 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
V1* M 30 24 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
V2* F 35 21 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
V3* M 31 23 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
W1* F 14 7 c.1102T.C p.(Tyr368His) c.11+5 G.A p.(?)
X1 M 38 15 c.271C.T p.(Arg91Trp) c.1067dup p.(Asn356Lysfs*9)
X2 F 53 32 c.271C.T p.(Arg91Trp) c.1067dup p.(Asn356Lysfs*9)
Y1 M 18 NA c.271C.T p.(Arg91Trp) c.271C.T p.(Arg91Trp)
Y2 F 7 4 c.271C.T p.(Arg91Trp) c.271C.T p.(Arg91Trp)
Y3 M 19 15 c.271C.T p.(Arg91Trp) c.271C.T p.(Arg91Trp)
Z1 F 20 16 c.1102T.C p.(Tyr368His) c.1543C.T p.(Arg515Trp)
AA1 M 33 29 c.11+5 G.A p.(?) c.499 G.T p.(Asp167Tyr)
AB1* M 30 20 c.11+5 G.A p.(?) c.11+5 G.A p.(?)
AB2* M 32 7 c.11+5 G.A p.(?) c.11+5 G.A p.(?)
AC1 F 27 9 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
AD1 M 8 1 c.715T.G p.(Tyr239Asp) c.715T.G p.(Tyr239Asp)
AE1* M 16 14 c.1102T.C p.(Tyr368His) c.991-993dup p.(Trp331dup)
AF1* F 9 4 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
AG1* M 17 15 c.1102T.C p.(Tyr368His) c.1102T.C p.(Tyr368His)
*Stems from genetic isolate; MIPs, Molecular Inversion Probes.
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measurements were converted to Snellen visual acuity.
Low vision measurements were converted to logarithm
of the minimum angle of resolution (LogMAR) visual
acuity to enable graphic representation (counting fingers:
2.0, hand movements: 2.3,41 light perception 2.5, and no
light perception 2.6). Patients underwent Goldmann
kinetic visual field (VF) testing, full-field electroretinog-
raphy according to International Society for Clinical
Electrophysiology (ISCEV) protocol, and color fundus
photography (Topcon Great Britain Ltd, Berkshire,
United Kingdom). Spectral domain optical coherence
tomography (SD-OCT) and fundus autofluorescence
(FAF) (Spectralis; Heidelberg Engineering Ltd, Heidel-
berg, Germany) were performed in subjects if fixation
was possible. The median follow-up was 16 years and
ranged from a single visit to 38 years. A subset of pa-
tients received gene augmentation therapy (7 patients)8,42
or pharmacological substitution therapy (1 patient) with
synthetic 9-cis-retinyl acetate25 (Table 1). We have
excluded all post-treatment measurements of both eyes
of these patients from analysis. Visual impairment was
defined as either low vision (BCVA worse than 20/60
but equal or better than 20/400 and/or central VF diam-
eter of the V4e target smaller than 20° but equal or larger
than 10° in the better eye) or blindness (BCVA worse
than 20/400 and/or central VF diameter of the V4e target
smaller than 10° in the better eye) in accordance with the
WHO criteria.
Retinal Structure
Cross-sectional images along the horizontal merid-
ian of the central retina were obtained with commer-
cially available SD-OCT instruments (Spectralis,
Heidelberg Engineering) using a 20° single line scan
crossing the fovea. Spectral domain OCT examination
proved very difficult because most patients had nys-
tagmus or nystagmoid movements and could not fixate
on the internal target. For qualitative analysis, the best-
quality images were selected for each patient, and for
quantitative analysis, images were analyzed if manual
segmentation was achievable for at least two layers of
interest. We quantified thickness of the ganglion cell
layer (GCL), the outer nuclear layer (ONL), the
photoreceptor–RPE complex, and the total retina in
23 scans from 10 patients with RPE65-mediated IRDs
(median age: 17 years, range: 4–35 years). A normal
data set for the thickness of all four layers on SD-OCT
was obtained from 110 eyes from 56 controls (median
age: 30 years, range 5–77 years) without retinal or
vitreoretinal disease. The GCL was measured from
the retinal nerve fiber layer to the inner plexiform
layer; the ONL was measured from the outer plexiform
layer to the external limiting membrane (ELM); the
photoreceptor complex thickness was measured from
the ELM to the RPE, and the total retinal thickness
was measured from vitreous–retinal interface to the
Bruch membrane complex. The reference layers were
segmented manually by the same operator (L.H.M.P.)
using the thickness graphs in Heidelberg Eye Explorer
software (Heidelberg Engineering). To calculate the
thickness of the whole retina, ONL, GCL, and
photoreceptor–RPE complex as a function of distance
to the macula, points were placed on the segmented
Bruch membrane at equidistance locations using
Matlab (Version 2013b, The MathWorks). Sub-
sequently, at each point, a line perpendicular to the
Bruch membrane was obtained. The distance between
the intersection of this line and the segmented inter-
faces that delineate the layer of interest was used to
calculate the thickness information, which was nor-
malized for the left and right eyes. In addition, the
distance along the Bruch membrane was reported
relative to the location of the macula. At each point,
the 95% confidence interval and 95% percentile were
calculated from the normal data set. Differences in
mean thickness of retinal layers were analyzed in cases
and controls with a Mann–Whitney U test, both in
children and adults.
Molecular Diagnosis
The molecular diagnosis was made in 30 patients
using PCR amplification and subsequent Sanger
sequencing of the RPE65 gene. In 12 patients, muta-
tions were found using an arrayed primer extension
(APEX) microarray chip for LCA (Asper Biotech, Tar-
tu, Estonia) and in two patients using an APEX micro-
array chip for autosomal recessive retinitis pigmentosa
(Asper Biotech). In one patient, targeted analysis of
256 IRD-associated genes after exome sequencing was
performed.
Molecular Inversion Probes
An additional genetic analysis was performed in 35
subjects using MIP to sequence 108 IRD-associated
genes (see Table 1, Supplemental Digital Content 1,
http://links.lww.com/IAE/B126). These 108 genes rep-
resented all published nonsyndromic IRD-associated
genes known in October 2013. Variants were identified
and filtered by quality (.200· depth), by allele fre-
quency in gnomAD (,0.005) and by gene component
(exon, canonical splice sites, splice site acceptor, splice
site donor, and intron).
The study adhered to the tenets of the Declaration of
Helsinki, and all procedures were reviewed by the
Medical Ethics Committee of Erasmus Medical Cen-
ter. Patients or patients’ guardian provided a written
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informed consent to retrieve data from medical records
and analyze retrospective and prospectively acquired
molecular and clinical data.
Results
Disease Onset and Diagnosis
We studied a cohort of 45 patients with RPE65-
associated retinal dystrophy, 28 (62%) stem from
a genetic isolate in the north of the Netherlands. Pa-
tients were grouped per family in Table 1. Most pa-
tients were diagnosed with RPE65-associated IRD
within the first year of life. Parents reported the pres-
ence of nystagmus, lack of eye contact, night blind-
ness, or photoattraction. In one patient, low vision was
attributed to high myopia, and the correct diagnosis
was made at age 17. For three non-Dutch subjects,
information on the onset of disease was missing
because we could not retrieve historical data from their
country of origin. Nystagmus was observed in 33 pa-
tients, in nine patients, it was absent, and in three
patients, information on nystagmus was lacking. The
clinical diagnosis was confirmed by severely reduced
or nonrecordable electroretinographic responses
(Table 2) and DNA testing (Table 1). There were no
patients with late-onset retinal disease caused by
RPE65 mutations in our ophthalmogenetic clinic.
Fundus Features
Fourteen patients were evaluated by one of the
authors during the first year of life and 18 in early
childhood (before the age of 5 years). In seven patients
(22%), no abnormalities were noted at first visit. A
relative dark aspect of the RPE or RPE alterations was
observed in the macula in 13 patients, the fovea was
hypopigmented (Figure 1A) in one patient, and the
foveal reflex was absent in seven patients. Fourteen
patients had narrow blood vessels. Three patients
(9%) had hypopigmented, blond fundi, and nine pa-
tients (28%) had subtle RPE changes in the periphery.
In four children, white dots were apparent early in life,
but these disappeared with aging (Figure 2). Intrareti-
nal pigment migration and atrophy of the RPE only
became apparent in the second decade of life and was
first recorded at the age of 13 years. In 15 patients, no
intraretinal hyperpigmentations were seen at last visit
(median age: 8 years, range: 0–20 years).
Quantitative and Qualitative Analysis of Spectral
Domain Optical Coherence Tomography Images
The mean total retinal thickness was reduced in scans
from children (n = 12) between the ages of 5 and 19
years, compared with controls (n = 26) (P = 0.000002)
(Figure 3). The mean thickness of the GCL was com-
parable in patients and controls (P = 0.45), whereas the
mean thickness of the ONL (P = 0.000001) and the
outer retinal layers (P = 0.000001) was significantly
reduced in patients. The retinal lamellar architecture
was mostly well preserved; however, a better preserva-
tion did not seem to be associated with a better visual
function (Figure 4). Patients K1, W1, and AE1 (Figure
4, A–C) had an intact photoreceptor layer with a contin-
uous ELM and ellipsoid zone (EZ), but their visual
acuity was poor (hand movements) compared with pa-
tients within the same age category (at 4, 10, and 11
years of age). The EZ in these patients appeared less
intense than in controls, but there were no gross abnor-
malities visible. A single patient, Y2 (Figure 4D),
showed signs of central retinal degeneration at 8 years
old; the ELM was only discernible in the perifoveal
region but not in the fovea, and the EZ appeared to
be absent in the macular region.
In adults, the mean total retinal thickness was
reduced in patients (n = 8) compared with controls
(n = 78) (P = 0.002) (Figure 3). The GCL thickness
was comparable in patients and controls (P = 0.08). As
in children, the mean thickness of the ONL (P =
0.000009) and outer retinal layers (P = 0.0002) was
significantly reduced. A small subset of patients had
Table 2. Patient Characteristics (N = 45)
Median current
age (years)
28 (range 2–59 years)
Sex, no. males (%) 27 (60%)
Ethnicity
European, no. (%) 37 (81%)
African, no. (%) 5 (12%)
Asian, no. (%) 3 (7%)
Mean age at onset of
symptoms (years)
,1 (range 0–3)
Mean age at
diagnosis (years)
,1 (range 0–17*)
Refractive error,
spherical
equivalent (D)
21.75 (range 211.75 to +5.75)
Mean follow-up
time (years)
16 (range 0–38)
Electroretinogram
Median age (years) 1 (range 0–10)
Rods and cones
nonrecordable,
no. (%)
31 (86%)
Rods nonrecordable,
severely reduced
cone response,
no. (%)
5 (14%)
*One patient was incorrectly diagnosed as low vision associ-
ated with high myopia as a child, and the correct diagnosis was
made at age 17.
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a relatively well-preserved central retinal architecture
in their twenties, with both the ELM and EZ clearly
distinguishable in the foveal region (Figure 4, E–H).
Patients with preserved architecture had a better visu-
al function. Thirteen patients developed pronounced
atrophy of the RPE and photoreceptor layers in the
macula, as early as the age of 17 years. The atrophy
started in the perifoveal region and crept up to the
center of the fovea (Figure 1), causing severe visual
impairment.
Fig. 1. Macular abnormalities
in patients with RPE65-medi-
ated IRDs. Fundus images,
infrared images, and SD-OCT.
Patient T1, (A) the fovea ap-
pears hypopigmented, whereas
the pigmentation in the periph-
ery is coarse, (B) the outer reti-
nal layers appear to be
continuous over the length of
the retinal scan, and the ELM is
hard to distinguish and might be
absent. Patient Z1, (C) revealing
a small remaining hyperpig-
mented foveal island, (D) the
outer retina is disrupted with
central hyperreflective rem-
nants. Follow-up imaging of
patient U1 at age 22 (E and F),
and 7 years later (G and H). On
scan (E), the outer retina is dis-
rupted with hyperreflective
foveal lines visible, possibly
there is some remaining ELM,
ellipsoid, and/or interdigitation
zone. On the follow-up scan (F),
there is atrophy the outer retina,
a subfoveal hyperreflective
deposit with nasally possible
ELM remnants. Patient AA1 (I
and J), imaging reveals absent
outer retina with exception of
subfoveal and small parafoveal
areas with some sparing of the
ellipsoid/interdigitation zone but
absent ELM. Patient B1 (K)
with end-stage disease, (L) RPE
and Bruch membrane are intact,
the outer retina is completely
absent with some hyper-
reflective deposits on the RPE
that correspond to hyperpig-
mentation. There is also an epi-
retinal membrane present.
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Fundus Autofluorescence
In most patients, it was not possible to obtain good-
quality FAF images, due to absence of autofluores-
cence, poor fixation, and a photophobic reaction to
blue light. In 17 patients, FAF imaging was not
performed, and in 22 patients, the quality of the image
was too low for interpretation. In eight eyes from six
patients, we were able to produce images (Figure 5),
but with a bright appearance of the optic disk, indicat-
ing inaccurate sensitivity settings during acquisition;
therefore, care must be taken with interpretation. In
four patients, a hyperautofluorescent ring was visible
in the posterior pole. The diameter of this ring ranged
from the parafoveal area to encompass the entire pos-
terior pole (Figure 5, C–F).
Visual Function
The follow-up period was left-skewed because our
cohort was relatively young; the median age was 28
years (Table 2). Best-corrected visual acuity meas-
urements were available for 43 of 45 subjects; in one
subject, it was impossible to record reliable meas-
urements because of young age (,1 year) and in one
subject because of intellectual disability. The
median follow-up of visual acuity was 15 years
(Table 1). There was no correlation between visual
acuity and the presence of nystagmus. Nine patients
had high myopia (more than 26.00 D), and eight
patients had moderate myopia (between 23.00 D
and 26.00 D). The median refractive error was
21.75 D. In five patients, we measured a significant
difference in visual acuity between both eyes,
greater than the test–retest variability of four lines
(0.3 LogMAR), at two or more consecutive meas-
urements (Figure 6B). They were diagnosed with
amblyopia in the past in presence of amblyogenic
risk factors such as anisometropia, uncorrected
refractive error, or strabismus. Treatment of the
underlying cause (e.g., correction of refractive error,
patching, or strabismus surgery) could not improve
visual acuity of the amblyopic eye. In other patients,
the decreased visual acuity was symmetric.
The course of visual acuity for the best-performing
eye as a function of age is shown in Figures 6 and 7.
The variability in visual acuity between subjects is large
in the first decade of life, ranging from 20/20 to count-
ing fingers at 1 meter. However, visual acuity remained
stable in childhood and early adulthood, both in the
best- and worst-performing eye, but inevitably pro-
gresses toward blindness in the 5th decade of life
(Figures 6 and 7). In a subset of patients, this was the
result of pronounced atrophy of the fovea (Figure 1).
Kinetic VFs were available for 33 subjects and were
graded according to the WHO criteria for low vision
and blindness. In childhood, VFs reached beyond 20°
radius for the V4 target, but with increasing age, the
radius of the central VF decreased. At age 28, 50% of
patients met the criteria for low vision and at age 38
for blindness (Figure 7).
Electroretinography
Electroretinograms (ERGs) were performed at diag-
nosis and were not routinely repeated during follow-
up. Thirty-one patients had no detectable ERGs to any
stimuli, and five patients showed severely reduced
cone responses with extinguished rod responses.
Because we depended on retrospective data for ERG
Fig. 2. Retinal imaging of white
dots in a patient with RPE65-
mediated IRDs. Fundus photo-
graph (A and B) and OCT scan
(C) of patient W1 aged 10 years,
showing white sharp demarcated
dots at the level of the RPE and
outer segment. Black arrow in-
dicates the white deposits.
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testing from different centers, we could not compare
amplitude values or latency values.
Molecular Genetics
Biallelic variants in RPE65 are summarized in Table
1, and additional information on previously reported
isomerase activity, in silico functional analyses, and
allele frequencies in healthy persons is listed in Table
3. We found eight missense variants, three frameshift
variants, one intronic variant, and one splice site var-
iant. Three missense variants were previously tested
in vitro and were considered nonhypomorphic, as their
isomerase activity fell below 10% of the wildtype
Fig. 3. Thickness of retinal lay-
ers. Thickness measurements of
the total retina, GCL, ONL, and
outer retinal layer in 20 scans
from 10 patients with RPE65-
mediated IRDs. The gray band
represents the 95% confidence
interval, the dashed lines repre-
sent the 2.5th and 97.5th per-
centiles, and each colored line
represents a single line scan.
ONH, optic nerve head.
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protein.43,44 Twenty-one patients were homozygous
for p.(Thr368His), and seven patients were heterozy-
gous carriers, making it the most common variant in
our cohort (54%). This founder mutation was found in
eight of the 121,144 alleles (0.007%) in ExAC, but
exclusively in subjects of European descent. In addi-
tion, we found this variant in two of 3,184 alleles from
whole-exome sequencing data from a Dutch outbred
cohort, the Rotterdam Study (0.04%).45
Molecular Inversion Probe testing in 35 patients
picked up all RPE65 variants that were previously
identified as causal by other DNA analysis techniques
(see Table 1, Supplemental digital content 2, http://
links.lww.com/IAE/B127). In 25 patients (71%), no
variants in other IRD-associated genes were identified
after filtering. In 10 patients, eight different variants
were detected, of which two were classified as benign
(MERTK and PDE6B), four were classified as likely
benign (ABCA4, CACNA1F, EYS, and USH2A), one as
likely pathogenic (EYS), and one as pathogenic
(LRAT) according to American College of Medical
Genetics and Genomics (ACMG) guidelines46 (Table
1, Supplemental Digital Content 2). The likely path-
ogenic EYS variant p.(Trp558*) was present heterozy-
gously in two siblings (K1, K2) who originated from
the genetic isolate. The pathogenic LRAT variant was
previously described by Littink et al,47 in the same
genetic isolate, and leads to a frameshift. This variant
was found heterozygously in a single patient (O3) who
also stemmed from this isolate.
Fig. 4. Spectral domain OCT
scans in patients with RPE65-
mediated IRDs. Spectral domain
OCT scans showing preservation
of the lamellar architecture of the
retina in patient K1 (A) and
patient W1 (B) appears, with
a normal ELM. In patient AE1
(C), the outer retina appears
normal in the center, but toward
the optic nerve, there is atrophy.
The ONL appears thinner than in
normal subjects, the ELM and
EZ are continuous, and the
foveal bulge is present. The EZ
appears less intense, compared
with healthy controls in A, B
and C. Spectral domain OCT of
patient Y2 (D) shows a disrup-
tion of the subfoveal and atrophy
of the parafoveal outer retina,
with subfoveal and extrafoveal
remnants of the outer retina but
hard to distinguish between
ELM/ellipsoid or interdigitation
zone. These remnants are lost
toward more peripheral areas.
Imaging in patient F1 (E),
patient M1 (F), patient AB1 (G),
and patient 01 (H) reveals
a well-preserved central retinal
architecture, with both the ELM,
interdigitation zone, and EZ
clearly distinguishable in the
center and parafoveal atrophy of
these outer layers in various
degrees.
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Genotype–Phenotype Correlation
There was no significant difference in course of
disease in subjects with different combinations of
variants. We plotted all BCVA measurements against
age for all patients in Figure 6. Patients homozygous for
the founder variant p.(Tyr368His) did not appear to
perform significantly better or worse than subjects with
other genotypes, and their visual performance was not
clustered but spread over the whole range of BCVA
values at different ages. The interfamilial and intrafami-
lial variability in visual function was high, even in pa-
tients with an identical RPE65 genotype. We compared
visual function of siblings from two families (Figure 8),
one homozygous for c.11+5 G.A (Family AB) and the
second homozygous for p.(Thr368His) (Family O)
within the same age range and observed a large hetero-
geneity in visual function. Patient AB2 showed atrophy
of the macula, at age 32, while his brother (AB1) was
still able to read print at age 30. In Family O, the eldest
brother (O3) had a better visual function than his youn-
ger siblings (O1-2) from childhood onward.
Discussion
In this study, we assessed the natural course of the
disease of RPE65-mediated IRDs by analyzing longi-
tudinal data from a large cohort of subjects (n = 45)
with biallelic pathogenic RPE65 variants, of which 28
subjects stem from a genetic isolate. This genetic
homogeneity of a large part of the study population
gave us the unique opportunity to look for genotype–
phenotype correlations. Our study shows that visual
function varies widely early in life but deteriorates
inevitably toward blindness. The percentage of pa-
tients meeting the WHO criteria for blindness in-
creases with age and reaches 100% after the age of 40
years. We did not observe a correlation between the
RPE65-genotype and the phenotype in this study, and
visual function varied significantly even between sib-
lings. Additional screening of 108 IRD-associated
genes in 35 patients revealed a single pathogenic
LRAT variant in one patient and a novel likely patho-
genic EYS variant in two siblings, in addition to the
previously detected RPE65 variants. Hence, there were
no patients with double hit IRDs.
RPE65-associated IRD was diagnosed within the
first year(s) of life in patients born in the Netherlands.
In the genetic isolate, the awareness toward RPE65-
mediated IRDs was high, as many inhabitants had
affected family members, and the disease prevalence
was markedly elevated. Hallmarks of RPE65-mediated
IRD are severe night blindness and photoattraction
from infancy caused by the rod–cone dystrophy.18,48
Fig. 5. Fundus autofluorescence
in patients with RPE65-mediated
IRDs. Fundus autofluorescence
imaging in patient O3 (A and B)
and patient O2 (C) shows
a small hyperautofluorescent
ring around the fovea. In patient
AA1 (D and E) and patient V2
(F), the macula appears partially
hyperautofluorescent.
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Nystagmus can be observed but is not inherent to
RPE65-mediated IRD and was not directly correlated
to visual acuity in our cohort. In the Netherlands,
genetic testing is routinely performed in infants, but
also in older patients newly diagnosed with IRDs. Up
until now, we have not come across patients with late-
onset RPE65-mediated IRDs in our clinics.
Infants with RPE65-associated IRDs had subtle fun-
duscopic changes (hypopigmentation, RPE alterations,
and narrow blood vessels). Signs of retinal degenera-
tion, such as bone spicule pigmentations, and atrophy
of the RPE, only became apparent in the second
decade of life. Thirteen patients developed perifoveal
atrophy, from as early as the age of 17 years, which
advanced toward the fovea and proved detrimental for
visual performance.
Spectral domain OCTs were selected based on their
quality and suitability for manual segmentation and
compared with OCTs of controls. It was challenging to
make good-quality scans, in patients with poor visual
function and severe nystagmus; as a consequence, our
results may lack the severe end of the spectrum. We
confirm that retinal lamellar architecture in the macula
was mostly preserved in children.15,20,49,50 One child
showed signs of retinal degeneration on OCT at an
early age (Figure 4D). Children with preserved lamel-
lar structure did not always have good visual acuity,
and the EZ appeared less intense than in controls. This
may be due to the RPE65 dysfunction. In adults, how-
ever, clearly distinguishable retinal layers in the fovea
(Figure 4, E–H) were associated with visual acuity that
was remarkably better than in patients with pro-
nounced atrophy. The ONL and outer retinal layer
were significantly thinner in patients in all age catego-
ries compared with controls (Figure 3). Outer nuclear
layer thickness is often used as a marker for retinal
remodeling in different types of IRDs.51–53
Fundus autofluorescence is based on the excitation
of fluorophores in lipofuscin, which is a byproduct of
the visual cycle. RPE65 is a key enzyme of the visual
cycle as it transforms all-trans-retinyl esters into 11-cis
retinol; thus, patients with RPE65-associated IRDs
might not be able to form lipofuscin at all. Previous
studies showed absent or very low autofluorescence
levels in patients17,54 and mice with RPE65-mediated
IRDs.43 Hypomorphic RPE65 mutations were associ-
ated with residual protein activity in in vitro studies.
As lipofuscin levels were proposed as a surrogate for
RPE65 activity, there should be enhanced autofluores-
cence present in patients with hypomorphic muta-
tions,26 but we did not have any patients with
previously tested hypomorphic mutations (Table 3).
Fundus autofluorescence with 488 nm was absent in
our patients. Even generating cSLO FAF images with
Fig. 6. Visual acuity as a function of time and comparison of visual acuity measurements between both eyes measured in a single visit. Measurements
of subjects homozygous for the p.(Thr368His) founder mutation are represented by black dots, measurements in subjects with other genotypes are
represented by white dots, and subjects from previous publications8,16–37 are represented by gray dots. A. Scatterplot of BCVA measurements of the
best eye in dependence of age. WHO criteria for blindness (BCVA , 20/400; dark gray) and low vision (20/60 . BCVA $ 20/400; light gray) are
marked. B. Scatterplot of VA measurements of the left eye in dependence of the right eye. The gray-filled banner represents the test–retest variability of
4 lines (0.3 LogMAR), which corresponds to 15 ETRDS letters. Fifty-six measurements of 19 patients were outside the range of 4 lines (0.3 LogMAR)
difference: In 8 patients, the difference was measured on one occasion, and in 11 patients, the difference was measured on 2 or more occasions. OD,
right eye; OS, left eye.
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inadequate sensitivity settings proved difficult in this
patient group because of nystagmus, poor fixation, and
patients’ discomfort. Overall autofluorescence in our
cohort was reduced compared with controls. In two
patients, of which one carried at least one nonhypo-
morphic variant (Figure 5, D and E) and a second
patient with a homozygous nonhypomorphic variant
(Figure 5F), the macula appeared hyperautofluorescent
compared with the midperiphery. Two patients with
nonhypomorphic mutations had a hyperautofluorescent
ring around the fovea (Figure 5, A and C) as typically
observed in patients with rod–cone dystrophies such as
retinitis pigmentosa.55 This ring has also been
observed in hypomorphic RPE65 mutations by Hull
et al,26 but judging from the aspect of the optic nerve,
these images seemed also to be acquired with subop-
timal exposure settings. Consequently, we cannot cer-
tify that the hyperautofluorescent signal in our subjects
was produced by lipofuscin, and care must be taken
with interpretation.
Loss of isomerization activity typically leads to
overaccumulation of all-trans-retinyl esters. Animal
models show that white dots are accumulations of
retinyl esters within lipid droplets.5,56,57 They are often
observed in patients with retinol dehydrogenase 5
(RDH5)-, retinaldehyde binding protein 1 (RLBP1)-,
and lecithin retinol acyltransferase (LRAT)-associated
fundus albipunctatus, fundus albipunctatus associated
with cone–rod disease, and retinitis punctata albes-
cens. All three genes are part of the vitamin A cycle.
We have observed white dots in one patient with
severe visual impairment at a young age and three
patients with moderate visual impairment. The pres-
ence of white dots has previously been associated with
Fig. 7. Course of visual acuity and VF as a function of time. Stacked bar-charts showing the distribution of BCVA per age category (A) in our study
cohort and (B) in pooled data from previously published studies,8,16–37 only data before treatment were included for analysis. When multiple meas-
urements were available for a patient within one decade, the mean was taken. The percentage of patients meeting the criteria for legal blindness in-
creases with age and reaches 100% over the age of 40 years in both populations. C shows the distribution of VF per age category. There were no
published data available for comparison. Low vision and blindness criteria were in accordance with the World Health Organization.
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both mild23,26 and severe24 disease phenotypes. It
might prove difficult to identify white dots in patients
with nystagmus or a blond aspect of the fundus; fur-
thermore, these dots disappear over time, which might
have led to an underestimation of its prevalence in our
cohort. Drüsen-like deposits are a common feature in
patients with IRDs and might resemble white dots
strongly. We are reluctant to associate white dots with
a more severe disease phenotype because we observed
them in four cases only.
Visual acuity in the first decade of life ranged from
20/20 to counting fingers at 1 m. A larger proportion
of children were visually impaired in our cohort when
compared with pooled visual acuity data from pre-
vious publications8,16–37 (Figure 7, A and B). Most
subjects were able to learn to read print as a child,
and visual acuity remained stable until adolescence.
We did not measure a transient improvement in visual
acuity in childhood, as suggested by Perrault et al.48
Five patients had one amblyopic eye with a difference
in visual acuity of more than four lines (0.3 LogMAR).
In the majority, visual acuity was symmetric between
both eyes. Over the age of 40 years, all patients were
blind according to WHO criteria for visual acuity
(Figure 7, A and B) because of progressive retinal
degeneration. These findings are consistent with a recent
publication by Chung et al58; visual acuity in the first
three decades was slightly better in our cohort. This
may be due to a difference in approach of analyzing
visual function data, as we looked at visual acuity of the
best- and worst-performing eye, while Chung et al
made a distinction between the right and left eye. We
were not able to compare VF results as we used a qual-
itative, rather than a quantitative method.
We observed considerable variability in visual
function between patients, even in subjects carrying
identical RPE65 variants. In 19 subjects who were
homozygous for the p.(Thr368His) variant, the sever-
ity of disease in the first four decades of life differed
substantially (Figures 6 and 7). Even among siblings,
who share more genetic material (50%) and were
exposed to similar environmental factors during child-
hood, the course of disease varied widely (Figures 6A
and 8). The p.(Thr368His) variant was previously
described as a nonhypomorphic variant, functional in
vitro studies revealed it had only ,3% isomerization
activity compared with wild type.59 Despite carrying
a homozygous mutation that severely diminishes
isomerization activity (i.e., nonhypomorphic residues),
some subjects had a good visual function at an early
age up to young adulthood. This mild phenotype was
previously described21,26 in four patients carrying mis-
sense mutations, resulting in hypomorphic residues,
but not in patients with nonhypomorphic residues.
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Fig. 8. Comparison of fundus images, BCVA measurements, infrared (IR) images, SD-OCT scans, and Goldmann VFs of siblings of two families within
the same age range. In family AB, the eldest brother (AB2) had markedly worse BCVA and smaller VF than his younger brother (AB1). Fundus imaging,
IR, and SD-OCT demonstrate (A and B) (AB1) central atrophy of the outer retina: The ELM is absent, and ellipsoid zone and interdigitation zone are
disrupted. His brother (D and E) (AB2) has a distorted inner retinal architecture and no recognizable ELM. The ellipsoid zone and interdigitation zone
appear intact in the macula. Both siblings have a peripheral island temporally; the oldest sibling (C) has a small remaining central VF with a radius below 5°
measured with the V4 target, and the youngest sibling (F) has a central VF of 15° radius measured with the V4 target and 10° with the III4 target. In family
O, the eldest sibling (O3) has a markedly better BCVA and larger VF (I, L, O) than his siblings (O1, O2) which is not clearly reflected in SD-OCT imaging.
He has (G, H) parafoveal atrophy of the outer retina with central sparing of the ellipsoid and interdigitation zone, outer retinal tubulation, and there appear to
be some remnants of the ELM. His sister (J, K) (O2) has similar parafoveal atrophy of the outer segments with sparing of the ellipsoid and interdigitation
zone. The youngest sibling (M, N) (O1) has parafoveal atrophy of the outer segments; it is not possible to distinguish the remaining outer retinal layers in
the center because of the quality of the scan. The VF of the oldest sibling (I) (O3) is relatively well preserved and reaches 60° temporally and 30° nasally
with the V4 target, and the VF of his younger sister (L) (O2) is markedly smaller and barely reaches 30° temporally and 10° nasally with the V4 target. The
youngest sibling (O) (O1) has a very small tunnel vision with a radius less than 5° and a small temporal peripheral island.
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So, the RPE65 genotype appeared to have no prognos-
tic value for the visual performance and disease pro-
gression in our cohort. Explanations for clinical
variation may be sought in reduced penetrance, differ-
ential allelic expression, copy number variation, or
modifying genetic variants in cis or trans.60 To zoom
in on the latter, we screened 108 IRD-associated genes
for pathogenic variants that may influence the pheno-
type. Visual cycle genes were of special interest, such
as ABCA4, LRAT, and RDH12. In addition, we wanted
to rule out a double hit because there was a high prev-
alence of consanguinity in our cohort, and there were
patients with FAM161A-, LRAT-, and USH2A-associ-
ated IRDs in the genetic isolate.
Molecular Inversion Probe analysis of 108 IRD-
associated genes confirmed all previously sequenced
RPE65 variants. We detected a heterozygous frame-
shift variant in LRAT in one patient, and a heterozygous
nonsense EYS variant in two siblings, all three stem-
ming from the genetic isolate. The LRAT variant was
described in four patients with retinitis punctata albes-
cens, originating from the same genetic isolate.47 The
LRAT gene is involved in the visual cycle; it catalyzes
the esterification of all-trans-retinol into all-trans-
retinyl ester, which is later transformed by RPE65 into
11-cis-retinol. Whether this frameshift LRAT variant
could have a modifying effect on the visual cycle,
and thus on the retinal dysfunction in patients with
RPE65-associated IRDs, remains to be identified.
Patient O3, who carried this variant, had a relatively
mild phenotype, which does not suggest a very dele-
terious effect of the additional LRAT variant. The
novel EYS variant found in two siblings (K1, K2) in-
duces a premature stop codon and is predicted to be
pathogenic. EYS is not part of the visual cycle but is
responsible for the structural integrity of photoreceptor
cells. One in four to five (20%–25%) individuals from
the general world population was estimated to be a car-
rier of a mutation in any IRD gene.61 In our study, 3 of
35 (9%) individuals carried a pathogenic variant in
another IRD gene, in addition to the biallelic RPE65
variants.
Up to now, gene therapy has improved patients’ mobil-
ity in dim light, enlarged VF, and sometimes improved
visual acuity, all to varying degrees.8,10–12,42,62–65 Serious
adverse events were rare (e.g., endophthalmitis, macular
hole, and retinal thinning), but treatment proved not to be
without risk, and the degenerative process was not slowed
by the intervention. Preintervention visual function in
younger patients was often better than in adults at baseline;
therefore, it was hard to assess age-dependent effects of
treatment. However, we advocate to initiate treatment as
early as possible, to target more viable photoreceptor cells,
and to stay ahead of the degenerative component.8,10–12
There was no consensus on whether the fovea needs to
be included within the subretinal vector bleb, but if
treated, it was recommended to keep the injected vol-
ume small to minimalize the foveal dehiscence.8,12
Atrophy of the fovea might make it difficult to spread
the vector bleb after injection; second, the gain in visual
acuity might be limited because there are little viable
photoreceptors left that benefit from treatment. High
myopia and the associated retinal thinning were consid-
ered a contraindication for foveal treatment.11
Over the past decades, we have closely followed
a cohort of 45 patients with RPE65-mediated IRDs to
gain insight into the course of disease and assess geno-
typic and phenotypic heterogeneity. The most impor-
tant limitation of this study is inherent to its
retrospective design. Data were gathered over five dec-
ades, and therefore, not all measurements were avail-
able for all patients. In our clinic, SD-OCT imaging
became available in 2008, followed by FAF imaging.
In patients with RPE65-mediated IRDs, the quality of
these techniques is often limited by the inability of
central fixation because of nystagmus and photoaver-
sion. For future studies, we suggest the combination of
multimodal imaging with fundus-controlled perimetry
to better correlate visual function with retinal structure.
All patients developed symptoms within the first year
of life. Most children had retinal abnormalities at first
examination. Visual function early in life varied and
remained stable until adolescence, but deteriorated
inevitably toward blindness after the age of 40 years.
Thirteen patients developed profound atrophy of the
macula during follow-up; this process started in the
perifoveal region and reached the fovea over the
course of years. We did not perceive a prognostic
value of the RPE65 genotype in our cohort. Three of
35 (9%) patients tested with MIP analysis carried an
additional pathogenic variant in another IRD-
associated gene (LRAT and EYS). No patients could
be diagnosed with a double hit IRD.
Key words: gene therapy, genetics, inherited retinal
degeneration, Leber congenital amaurosis, optical
coherence tomography, RPE65, retinitis pigmentosa,
visual field.
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